GALT
Galectin Converts $105.8M in Debt to Equity
Chairman Richard E. Uihlein converted $105.8 million in outstanding debt into 34.4 million common shares, significantly strengthening the biopharmaceutical company's balance sheet.
GALT news
Latest 2 stories · newest Aug 4, 2026
GALT
Galectin Therapeutics Agrees With FDA On Belapectin For MASH Cirrhosis
Galectin Therapeutics reached an agreement with the FDA on the primary endpoint and regulatory pathway for belapectin in MASH cirrhosis patients. This alignment clarifies the Phase 3 protocol and supports the company's evaluation of strategic partnerships to support development.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same GALT feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/GALT/newsSTART FREE